色氨酸 20 号终止突变及其与结核分枝杆菌 4.5 谱系和对德拉马尼和贝达喹啉耐药性的关联。
The Trp20Stop Mutation and Its Association with Lineage 4.5 and Resistance to Delamanid and Pretomanid in Mycobacterium tuberculosis.
机构信息
Public Health Agency of Swedengrid.419734.c, Solna, Sweden.
出版信息
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0102622. doi: 10.1128/aac.01026-22. Epub 2022 Nov 21.
Abstract
High-confidence resistance mutations for new and repurposed anti-TB drugs, such as delamanid (DLM) and pretomanid (Pa), are rare and more data are needed in order to correctly interpret the results generated by genotypic drug susceptibility testing. In this study performed on clinical Mycobacterium tuberculosis complex isolates, we report that in the Swedish strain collection the mutation Trp20Stop is found exclusively among DLM and Pa resistant (Pa MIC >16 mg/L) isolates assigned to lineage 4.5.
摘要
高可信度的耐结核新药（如德拉马尼[DLM]和普托马尼[Pa]）耐药突变较为罕见，需要更多数据才能正确解读基因型药物敏感性试验的结果。本研究对临床结核分枝杆菌复合群分离株进行分析，报告称在瑞典菌株集中，Trp20Stop 突变仅存在于 DLM 和 Pa 耐药（Pa MIC＞16mg/L）株中，且这些耐药株均属于谱系 4.5。
相似文献
1
The Trp20Stop Mutation and Its Association with Lineage 4.5 and Resistance to Delamanid and Pretomanid in Mycobacterium tuberculosis.色氨酸 20 号终止突变及其与结核分枝杆菌 4.5 谱系和对德拉马尼和贝达喹啉耐药性的关联。
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0102622. doi: 10.1128/aac.01026-22. Epub 2022 Nov 21.
2
Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis.比较硝基咪唑类药物德拉马尼和普托马尼对耐多药和广泛耐药结核病的体外活性。
Eur J Clin Microbiol Infect Dis. 2019 Jul;38(7):1293-1296. doi: 10.1007/s10096-019-03551-w. Epub 2019 Apr 5.
3
A Narrative Review of Bedaquiline and Delamanid: New Arsenals Against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis.贝达喹啉和德拉马尼的叙述性综述：针对耐多药和广泛耐药结核分枝杆菌的新武器。
J Clin Lab Anal. 2024 Aug;38(15-16):e25091. doi: 10.1002/jcla.25091.
4
Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.结核分枝杆菌复合体临床分离株中新药和再利用药物表型耐药相关的基因组突变及其相关性研究。
J Antimicrob Chemother. 2023 Nov 6;78(11):2637-2644. doi: 10.1093/jac/dkad252.
5
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.新型和重新定位的抗结核分枝杆菌药物贝达喹啉、氯法齐明、利奈唑胺、德拉马尼和普托马尼耐药相关突变的系统评价。
J Antimicrob Chemother. 2020 Aug 1;75(8):2031-2043. doi: 10.1093/jac/dkaa136.
6
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.与利福平、贝达喹啉和德拉马尼耐药相关候选基因座的遗传多样性。
Sci Rep. 2021 Sep 30;11(1):19431. doi: 10.1038/s41598-021-98862-4.
7
High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant isolates.全球广泛耐药结核分离株中新推荐抗结核药物的高聚类率和基因型药物敏感性筛查。
Emerg Microbes Infect. 2022 Dec;11(1):1857-1866. doi: 10.1080/22221751.2022.2099304.
8
Delamanid or pretomanid? A Solomonic judgement!德拉马尼还是普雷马尼？这真是一个棘手的问题！
J Antimicrob Chemother. 2022 Mar 31;77(4):880-902. doi: 10.1093/jac/dkab505.
9
Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients.结核分枝杆菌天然突变株导致初治患者对德拉马尼耐药。
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.00513-20.
10
Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis.结核分枝杆菌中德拉马尼耐药的自发突变模式和新突变。
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0053122. doi: 10.1128/aac.00531-22. Epub 2022 Nov 30.
引用本文的文献
1
High-Level Primary Pretomanid-Resistant with In-Frame Deletion of and Its Association with Lineage 4.5 in China.中国高水平对 Pretomanid 原发性耐药且伴有框内缺失及其与 4.5 谱系的关联
ACS Omega. 2025 Jun 23;10(25):26551-26559. doi: 10.1021/acsomega.5c00610. eCollection 2025 Jul 1.
2
Performance of a broth microdilution assay for routine minimum inhibitory concentration determination of 14 anti-tuberculous drugs against the complex based on the EUCAST reference protocol.基于欧盟CAST参考协议，采用肉汤微量稀释法对14种抗结核药物针对该菌群进行常规最低抑菌浓度测定的性能。
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0094624. doi: 10.1128/aac.00946-24. Epub 2024 Dec 18.
本文引用的文献
1
Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field.下一代测序技术在耐多药结核病诊断和临床管理中的应用：该领域最新进展综述
Front Microbiol. 2022 Mar 24;13:775030. doi: 10.3389/fmicb.2022.775030. eCollection 2022.
2
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid.结核分枝杆菌复合群固有易感性在古今之间的差异。
J Antimicrob Chemother. 2022 May 29;77(6):1685-1693. doi: 10.1093/jac/dkac070.
3
Delamanid or pretomanid? A Solomonic judgement!德拉马尼还是普雷马尼？这真是一个棘手的问题！
J Antimicrob Chemother. 2022 Mar 31;77(4):880-902. doi: 10.1093/jac/dkab505.
4
Genomic signatures of pre-resistance in Mycobacterium tuberculosis.结核分枝杆菌耐药前的基因组特征。
Nat Commun. 2021 Dec 15;12(1):7312. doi: 10.1038/s41467-021-27616-7.
5
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid.与利福平、贝达喹啉和德拉马尼耐药相关候选基因座的遗传多样性。
Sci Rep. 2021 Sep 30;11(1):19431. doi: 10.1038/s41598-021-98862-4.
6
Adduct Formation of Delamanid with NAD in Mycobacteria.结核分枝杆菌中德拉马尼与烟酰胺腺嘌呤二核苷酸的加合物形成。
Antimicrob Agents Chemother. 2020 Apr 21;64(5). doi: 10.1128/AAC.01755-19.
7
Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex.结核分枝杆菌复合体中与抗生素耐药性相关基因的系统发育信息性突变。
Genome Med. 2020 Mar 6;12(1):27. doi: 10.1186/s13073-020-00726-5.
8
Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering.利用蛋白质工程预测结核分枝杆菌中的硝基咪唑类抗生素耐药突变。
PLoS Pathog. 2020 Feb 7;16(2):e1008287. doi: 10.1371/journal.ppat.1008287. eCollection 2020 Feb.
9
Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC™ MGIT™ 960 system.使用刃天青微量滴定法和BACTEC™ MGIT™ 960系统对结核分枝杆菌进行地拉曼id药敏试验。
J Antimicrob Chemother. 2016 Jun;71(6):1532-9. doi: 10.1093/jac/dkw044. Epub 2016 Apr 13.
10
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.OPC-67683，一种硝基二氢咪唑并恶唑衍生物，在体外和小鼠体内对结核病有显著疗效。
PLoS Med. 2006 Nov;3(11):e466. doi: 10.1371/journal.pmed.0030466.
Zotero 插件